Area of research
Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine
Research interest
Research interests include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Sarcoidosis and Beryllium Toxicity Research, and Medical Imaging and Pathology Studies.
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis
Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis
Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials
Comprehensive assessment of the long‐term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
Genetic determinants of pulmonary fibrosis: evolving concepts
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
Rare lung disease and orphan drug development